SMNR

Semnur Pharmaceuticals, Inc.

Price Chart

Latest Quote

$3.00

-1.89 (-38.65%)

Current Price

Previous Close	$4.89
Open	$2.80
Day High	$3.00
Day Low	$2.50
Volume	1,550

Fetched: 2026-06-15T22:54:19

Stock Information

Shares Outstanding	230.21M
Total Debt	$19.68M
Cash Equivalents	$103K
Net Income	$-164.33M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$690.63M
EPS (TTM)	$-0.71
Exchange	PNK

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$664.17M
Income	$-164.33M
Book/sh	$-0.11
Cash/sh	$0.00
Employees	10

Financial Ratios

Quick Ratio	0.01
Current Ratio	0.12

Returns & Margins

ROA

-2166.30%

Ownership

Insider Ownership	87.34%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-27.27

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$4.60
SMA50	$5.90
RSI	39.98
ATR	0.7593

Shares Float	29.71M
Rel Volume	5.44

Performance History

Week	-40.00%
Month	-49.92%
Quarter	-62.50%
6 Months	-66.67%
YTD	-86.96%
10 Years	-85.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-15	$3.00	1,550
2026-06-12	$2.80	440
2026-06-11	$4.89	0
2026-06-10	$4.89	502
2026-06-09	$3.10	404
2026-06-08	$5.00	0
2026-06-05	$5.00	0
2026-06-04	$5.00	0
2026-06-03	$5.00	0
2026-06-02	$5.00	500
2026-06-01	$4.95	226
2026-05-29	$3.40	1,246
2026-05-28	$3.00	0
2026-05-27	$3.00	207
2026-05-26	$5.00	100
2026-05-22	$5.00	526
2026-05-21	$5.99	0
2026-05-20	$5.99	0
2026-05-19	$5.99	0
2026-05-18	$5.99	0

About Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

📰 Latest News

No news articles available at the moment. Check back later for updates on SMNR.

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Total Expenses	$4,690,000	$3,261,000	$3,765,000
Operating Expense	$4,690,000	$3,261,000	$3,765,000
General And Administrative Expense	$2,981,000	$1,640,000	$1,647,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-4,690,000	$-3,261,000	$-3,765,000
Normalized Income	$-4,690,000	$-3,261,000	$-3,765,000
Net Income From Continuing And Discontinued Operation	$-4,690,000	$-3,261,000	$-3,765,000
Total Operating Income As Reported	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Common Stockholders	$-4,690,000	$-3,261,000	$-3,765,000
Net Income	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Including Noncontrolling Interests	$-4,690,000	$-3,261,000	$-3,765,000
Net Income Continuous Operations	$-4,690,000	$-3,261,000	$-3,765,000
Pretax Income	$-4,690,000	$-3,261,000	$-3,765,000
Operating Income	$-4,690,000	$-3,261,000	$-3,765,000
Per Share
Diluted EPS	$-0.02	$-0.01	$-0.02
Basic EPS	$-0.02	$-0.01	$-0.02
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-4,690,000	$-3,261,000	$-3,765,000
EBITDA (Bullshit earnings)	$-4,690,000	$-3,261,000	$-3,765,000
EBIT	$-4,690,000	$-3,261,000	$-3,765,000
Diluted Average Shares	$240,082,286	$240,082,286	$240,082,286
Basic Average Shares	$240,082,286	$240,082,286	$240,082,286
Diluted NI Availto Com Stockholders	$-4,690,000	$-3,261,000	$-3,765,000
Research And Development	$1,709,000	$1,621,000	$2,118,000
Selling General And Administration	$2,981,000	$1,640,000	$1,647,000
Other Gand A	$2,981,000	$1,640,000	$1,647,000

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-42,784,000	$-38,094,000	$-34,833,000
Total Assets	$6,684,000	$703,000	$762,000
Total Non Current Assets	$689,000	$689,000	$689,000
Current Assets	$5,995,000	$14,000	$73,000
Other Current Assets	$5,981,000	-	-
Prepaid Assets	$2,000	$2,000	$45,000
Cash Cash Equivalents And Short Term Investments	$12,000	$12,000	$28,000
Cash And Cash Equivalents	$12,000	$12,000	$28,000
Debt
Net Debt	$49,421,000	$37,889,000	$35,372,000
Total Debt	$49,433,000	$37,901,000	$35,400,000
Long Term Debt And Capital Lease Obligation	$49,433,000	$37,901,000	$35,400,000
Long Term Debt	$49,433,000	$37,901,000	$35,400,000
Liabilities
Total Liabilities Net Minority Interest	$49,468,000	$38,797,000	$35,595,000
Total Non Current Liabilities Net Minority Interest	$49,433,000	$37,901,000	$35,400,000
Current Liabilities	$35,000	$896,000	$195,000
Payables And Accrued Expenses	$35,000	$896,000	$195,000
Equity
Common Stock Equity	$-42,784,000	$-38,094,000	$-34,833,000
Total Equity Gross Minority Interest	$-42,784,000	$-38,094,000	$-34,833,000
Stockholders Equity	$-42,784,000	$-38,094,000	$-34,833,000
Retained Earnings	$-115,384,000	$-110,694,000	$-107,433,000
Other
Ordinary Shares Number	$240,082,286	$240,082,286	$240,082,286
Share Issued	$240,082,286	$240,082,286	$240,082,286
Tangible Book Value	$-42,784,000	$-38,094,000	$-34,833,000
Invested Capital	$6,649,000	$-193,000	$567,000
Working Capital	$5,960,000	$-882,000	$-122,000
Total Capitalization	$6,649,000	$-193,000	$567,000
Additional Paid In Capital	$72,598,000	$72,598,000	$72,598,000
Capital Stock	$2,000	$2,000	$2,000
Common Stock	$2,000	$2,000	$2,000
Preferred Stock	$0	$0	-
Current Accrued Expenses	$35,000	$896,000	$195,000
Net PPE	$689,000	$689,000	$689,000
Accumulated Depreciation	$-25,000	$-25,000	$-25,000
Gross PPE	$714,000	$714,000	$714,000
Construction In Progress	$689,000	$689,000	$689,000
Machinery Furniture Equipment	$25,000	$25,000	$25,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-4,891,000	$-1,677,000	$-4,043,000
Operating Activities
Operating Cash Flow	$-4,891,000	$-1,677,000	$-4,043,000
Cash Flow From Continuing Operating Activities	$-4,891,000	$-1,677,000	$-4,043,000
Financing Activities
Financing Cash Flow	$4,891,000	$1,661,000	$3,974,000
Cash Flow From Continuing Financing Activities	$4,891,000	$1,661,000	$3,974,000
Net Other Financing Charges	$-5,981,000	-	-
Other
Issuance Of Debt	$10,872,000	$1,661,000	$3,974,000
End Cash Position	$12,000	$12,000	$28,000
Beginning Cash Position	$12,000	$28,000	$97,000
Net Issuance Payments Of Debt	$10,872,000	$1,661,000	$3,974,000
Net Long Term Debt Issuance	$10,872,000	$1,661,000	$3,974,000
Long Term Debt Issuance	$10,872,000	$1,661,000	$3,974,000
Change In Working Capital	$-861,000	$744,000	$-1,150,000
Change In Payables And Accrued Expense	$-861,000	$701,000	$-1,340,000
Change In Accrued Expense	$-861,000	$701,000	$-563,000
Change In Prepaid Assets	$0	$43,000	$190,000
Stock Based Compensation	$660,000	$840,000	$872,000
Net Income From Continuing Operations	$-4,690,000	$-3,261,000	$-3,765,000
Changes In Cash	-	$-16,000	$-69,000
Change In Account Payable	-	$0	$-777,000
Change In Payable	-	-	$-777,000

Fetched: 2026-02-02